This ad will auto close in 10 seconds

FDCs banned over safety & efficacy concerns: Centre tells HC

The hearing in the matter would continue on April 4.  

P&G to resume manufacturing, sale of Vicks Action 500 Extra

FMCG firm Procter and Gamble (P&G) today said it will resume manufacturing and sale of its popular brand 'Vicks Action 500 Extra' after the Delhi High Court stayed government's order banning fixed dose combination drugs

HC restrains Glenmark from business of anti-diabetes drugs

HC restrains Glenmark from business of anti-diabetes drugs

In a relief for US drug major Merck Sharp and Dohme (MSD), Delhi High Court on Wednesday restrained Indian firm Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs Zita and Zita-Met, saying it has infringed patent of the American company.

Glenmark receives USFDA nod for oral contraceptive drug

"Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg," the company said in a BSE filing.

US court rejects Glenmark's patent plea for Finacea

Drug firm Glenmark's generic skin care drug that was under patent litigation infinges patent of Bayer, a US court has ruled.

Glenmark launches Teneligliptin for diabetes

 Glenmark Pharmaceuticals Limited here on Wednesday launched its advanced diabetes treatment molecule Teneligliptin under the brands Ziten and Zita plus, priced at Rs.19.90 per tablet and enough for a day's treatment.

Glenmark gets USFDA nod for generic diabetes treatment drug

Shares of Glenmark Pharmaceuticals were trading at Rs 874.75 per scrip in afternoon trade, up 2.04 percent from the previous close on the BSE.

Glenmark gets tentative USFDA nod to sell Rufinamide

Rufinamide is used to treat seizures caused by Lennox-Gastaut syndrome.

Glenmark to pay $24.96 mn to US to settle pricing probe

In a regulatory filing with the National Stock Exchange, the company said that under the terms of the agreed settlement, "there is no admission of liability".

Glenmark's subsidiary to pay $25 mn to settle a pricing case

Pharmaceutical major Glenmark on Wednesday said its US subsidiary will pay USD 25 million to the federal government there as well as to the Texas state administration to settle a pricing investigation.

Glenmark gets USFDA nod for post-menopause osteoporosis drug

The approval for sale of Norethindrone Acetate and Ethinyl Estradiol tablets was given to Glenmark Generics Inc USA, a subsidiary of Glenmark Generics Ltd.

SC stays Delhi HC order till April 28 against Glenmark

Supreme Court today stayedtill April 28 the order of Delhi High Court barring Indian pharma major Glenmark Pharamceuticals from making, marketing or selling its anti-diabetes medicines in which US drug major Merck Sharp and Dohme (MSD) has claimed patent right.

Glenmark gets USFDA nod to sell generic blood pressure drug

Glenmark Pharmaceuticals Thursday announced receipt of approval from the US health regulator to sell its generic version of AbbVie Inc's blood pressure drug Tarka in the American market.

FIPB refers Rs 4,197 cr Glenmark, Aurobindo proposals to CCEA

The Finance Ministry Thursday referred the foreign investment proposals worth Rs 4,187 crore in pharma firms - Glenmark and Aurobindo - to the Cabinet Committee on Economic Affairs.

FDI proposals worth Rs 1,075.91 cr cleared; Glenmark, Aurobindo sent to CCEA

FIPB has cleared foreign investment in 11 entities, entailing Rs 1,075.91 crore, and referred proposals worth Rs 4,187 crore in pharma firms - Glenmark and Aurobindo - to the Cabinet Committee on Economic Affairs.

Glenmark bullish on drug discovery pipeline, eyes partnerships

As many as six out of seven molecules in Glenmark's drug discovery pipeline are currently in the clinical trial stage and the company's R&D spend pegged at 10 percent of sales is expected to be maintained at similar levels for next two years, a top official has said.

Glenmark bullish on drug discovery pipeline, eyes partnerships

Pain, inflammation and oncology are the therapeutic areas currently the drug maker is working on, said Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd.

Glenmark Q3 net dips 47 pc at Rs 114.77 cr

Glenmark Pharmaceuticals today reported a 46.92 per cent dip in its consolidated net profit at Rs 114.77 crore for the quarter ended December 31, 2014 mainly due to forex losses and increased expenses.

HC sets aside restraint on Glenmark from making an antibiotic

Delhi High Court today set aside its single judge's order restraining Mumbai-based generic drug maker Glenmark Pharmaceuticals Ltd from making and selling its antibiotic medicine Linezolid.

Glenmark to set up first manufacturing facility in US

Glenmark Pharmaceuticals plans to set up its first manufacturing facility in the US at an estimated investment of over Rs 500 crore to cater to the North American market.